# Agentic Pre-Market Brief — 2026-11-03 (Tuesday)

- **Scheduled fire:** 2026-11-03 08:30 ET (`scheduled_at_ms` 1793712600000) — on time, not a replay.
- **Generated:** 2026-11-03 08:41 EST · **Screener data as of:** 08:33 ET
- **Market open:** 09:30 ET. Cash open in ~49 min at time of writing.
- **Scope:** the entire US-listed equity universe (`type` in stock/dr, NASDAQ/NYSE/AMEX) — the watchlist is a section, not the spine, and today it is absent (§6).
- **Price convention:** pre-market prints and `%ADV` are the TradingView public scanner; regular-session closes are cross-checked against the MCP-bridge `market-recap` (Yahoo-sourced). Every Nov-2 close quoted here matched on both sources to the cent.
- **Note on the `change` column:** on the `america` scanner `change` is the **last completed regular session** (Mon 2026-11-02) and `premarket_change` is the live pre-market gap vs that close. Both are shown; they are different sessions.

---

## 1. TL;DR — six themes, clustered

1. **Election day, and the tape is pricing it before the voters do.** Nov 3 is the US midterms — all 435 House seats and 35 Senate seats. Polls close from ~18:00 ET, so **no result lands before the cash close**. Options price ~0.86% for the session and 1.85% into Nov 6; a Democratic House is priced at 91-93%. The bigger risk today is the **AI trade repricing**, not the count: the Nasdaq-100 fell 1.36% Monday into correction territory while the Dow rose 0.43%, and a Democratic Congress would put the data-centre buildout under more scrutiny.
2. **Software and consumer-tech earnings are the day's dominant mover — and the market is paying for revenue quality, not for beats.** Down: **ADEA -20.9%**, **ZBRA -16.4%**, **SHOP -14.6%**, **DT -14.1%**, **DOCN -6.5%**, **PLTR -6.1%**, **AAPL -3.9%**. Up: **BLZE +37.1%**, **AEHR +17.6%**, **RVTY +10.2%**, **GRAB +10.5%**, **FISV +9.9%**. Nearly every decliner *beat or raised*: Adeia reiterated its $600M long-term target while cutting FY26 revenue, Zebra beat and raised and still fell, Dynatrace beat on EPS and revenue but trimmed FY guidance. The tape is trading **guidance credibility, not headlines**.
3. **Chips are bouncing, and AMD is the referee tonight.** **INTC +3.7%** pre-market after -8.8% Monday, **NVDA +1.9%**, **LSCC +11.0%**, **AEHR +17.6%**, **HLIT +17.4%**. **AMD reports after the close** on consensus **$13.08-13.09B revenue (+42% y/y)** and **$1.95 adjusted EPS**, with the ~56% gross-margin guide and Client revenue the lines to watch.
4. **Oracle's $20B raise has stopped hurting — but the stock sits only 2.8% above the offering price.** ORCL priced **86,206,897 shares at $116** (11.2% below the Oct 30 close) plus **$10B of senior notes at 7.00-8.65%**, closing Nov 4. ORCL fell **8.8%** Monday and is now **flat at $119.23** pre-market. The dilution is priced; the margin is thin.
5. **Marvell/Lumentum still carries a wide deal spread.** **MRVL -12.7%** and **LITE -18.6%** Monday on the $115B all-stock announcement (4.500 fixed ratio, ~$1,132 implied, +23.9% vs the Oct 28 unaffected close). Both are up ~2.4-2.8% pre-market, but at **MRVL $176.28** the implied LITE value is **$793.26** against a **$700.50** print — a **-11.7%** spread. Capital is locked to 1H CY28, so a persistent discount is pricing deal risk, not arbitrage.
6. **The biotech tape is fading where it spiked.** **INO +213.7%** Monday on the first FDA-approved DNA medicine (VOCERYQ) is **-7.9%** pre-market; **PGEN -25.9%** Monday is **+1.8%** today; **DRUG -52.3%** Monday is **-9.6%** today; **KPTI -83.1%** on the Chapter 11 filing is **-6.2%** today. **CMPS is the exception: +6.9%** pre-market on its own Q3 — final NDA filing within two weeks, National Priority Voucher review that could compress to 1-2 months.

**Tape breadth:** 262 names up ≥3% pre-market and 203 down ≤-3% across the US-listed universe. After the liquidity screen (≥100k pre-market shares, or ≥$200M cap with ≥10k shares) that is **66 up / 44 down**. This is **not a thin tape**. The risk is **concentration**: five of the ten largest liquid pre-market decliners are software, and the pre-market bid is concentrated in a small group of earnings reporters.

**Watchlist:** the personal watchlist file (`research/watchlist.yaml`) lives on the local Windows Mavis host and is **not reachable from the Cloud sandbox** — no copy exists in `karizaco/maxhermes-migration` or `karizaco/minimax-cloud-outputs`. No default was created; **no watchlist section is published today** (§6, Source health).

---

## 2. Theme clusters

### Cluster A — Q3 software & consumer tech: guidance credibility beats the headline beat

**Leader by magnitude: ADEA -20.9%.** Every name here reported either Mon after the close or Tue before the open; the pre-market gap *is* the earnings reaction.

| Ticker | Nov-2 close | Nov-2 % | Pre-market | % | Pm vol | %ADV | Mkt cap | What happened |
|---|---|---|---|---|---|---|---|---|
| **ADEA** | 20.67 | -3.6% | **16.35** | **-20.9%** | 53,671 | 4.5% | 2,279M | Q3 rev $80.2M (vs $96.1M Q2, $87.3M yr-ago); GAAP EPS $0.02, non-GAAP $0.21; adj EBITDA $36.9M vs $50.7M. FY26 revenue guide cut to $375-415M from $395-435M, adj EBITDA to $201.1-237.1M from $213.4-245.4M. $600M long-term target **reiterated**. |
| **ZBRA** | 361.13 | -0.0% | **302.01** | **-16.4%** | 5,768 | 0.1% | 17,085M | Q3 beat and raised outlook — **fell anyway on margin worries**. Print is on thin volume (0.1% of ADV). |
| **SHOP** | 156.22 | -0.8% | **133.39** | **-14.6%** | 821,746 | 9.1% | 200,965M | Q3 mixed: earnings and profitability **improved**, but merchandise sales came in weaker than expected — "slowing merchandise sales flash a warning sign". |
| **DT** | 55.13 | -4.4% | **47.38** | **-14.1%** | 398,253 | 5.3% | 15,933M | adj EPS $0.54 vs $0.49 est, rev $580M vs $568M est, ARR $2.21B (+16%) in line — **but** Q4 adj EPS guided $0.45 vs $0.51 est and FY $1.88-1.90 vs $1.96 est, after the $915M Arize acquisition closed Oct 1. |
| **DOCN** | 89.79 | +0.2% | **84.00** | **-6.5%** | 706,013 | 27.6% | 10,557M | Reported Q3 before the open Nov 3 (call 8:00 ET). Result detail **not sourced in this run**. |
| **PLTR** | 178.34 | -3.1% | **167.43** | **-6.1%** | 1,940,337 | 8.5% | 428,561M | Beat and raised — sold off anyway on valuation and slower contract-value growth vs accelerating commercial AI demand. |
| **AAPL** | 338.32 | -1.8% | **325.22** | **-3.9%** | — | — | 4,937,503M | After-hours slip on **rising memory costs** threatening margins despite strong iPhone sales. |
| **BLZE** | 7.40 | -2.5% | **10.15** | **+37.1%** | 301,384 | 14.4% | 458M | Q3 beat, revenue guidance raised, accelerating B2 cloud-storage growth — the AI-storage read-through. |
| **GRAB** | 2.86 | +5.5% | **3.16** | **+10.5%** | 7,175,449 | 10.4% | 11,665M | Q3 rev $1,112M (+27%), record adj EBITDA $237M (+73%), **all three segments profitable for the first time**, FY guide raised to $4.15-4.20B rev / $790-800M adj EBITDA (from $720-740M); 57M monthly users; $400M buyback done, $500M left. |
| **RVTY** | 151.60 | -3.4% | **167.00** | **+10.2%** | 10,467 | 0.5% | 16,916M | Q3 rev $729M, adj EPS $1.38, **full-year guidance raised**, Investor Day set for Nov 13. |
| **FISV** | 51.93 | +3.8% | **57.08** | **+9.9%** | 334,387 | 5.5% | 27,615M | Quarterly beat, FY outlook reaffirmed, cost-savings target raised, accelerated buybacks flagged. |
| **AEHR** | 51.47 | -6.2% | **60.55** | **+17.6%** | 174,660 | 6.9% | 1,681M | Record FQ1 revenue $33M (+200% y/y), FY27 outlook raised to $150M, bookings $46.7M (book-to-bill ~1.4), effective backlog $109.3M. |
| **IEP** | 5.16 | -0.6% | **5.60** | **+8.5%** | 98,833 | 7.9% | 3,668M | Trending #15. Catalyst **not sourced in this run** — flagged, not explained. |

**Read:** this is not an "earnings beat" tape, it is a **revenue-quality tape**. The four biggest decliners all passed the headline test and failed the guide. Adeia is the cleanest case: management cut the range and reiterated the $600M long-term target, and the stock took 21% off. The winners (BLZE, AEHR, RVTY, GRAB) all **raised** something tangible. The mechanism is that guidance credibility is now the binding constraint after three weeks of AI-capex-driven multiple compression.

**Sources:** [Adeia Q3 release](https://investors.adeia.com/news-releases/news-release-details/adeia-announces-third-quarter-2026-financial-results) · [Adeia 8-K](https://www.stocktitan.net/sec-filings/ADEA/8-k-adeia-inc-reports-material-event-11f58c0e54e0.html) · [IBD: Zebra + Dynatrace](https://www.investors.com/news/technology/dynatrace-stock-dt-dynatrace-earnings-news-q32026/) · [Barron's: Shopify](https://www.barrons.com/articles/shopify-earnings-stock-price-f5cec098) · [Grab Q3 release](https://www.grab.com/sg/press/others/grab-reports-third-quarter-2026-results-raises-full-year-guidance/) · [Revvity Q3](https://finance.yahoo.com/markets/stocks/articles/revvity-announces-financial-results-third-110000390.html) · [Aehr beat-and-raise](https://seekingalpha.com/news/4663209-aehr-stock-jumps-on-beat-and-raise-amid-ai-demand) · [DigitalOcean IR](https://investors.digitalocean.com/news/news-details/2026/DigitalOcean-Announces-Date-of-Third-Quarter-2026-Earnings-Conference-Call/default.aspx)

### Cluster B — Semis rebound from Intel's PC warning; AMD is the referee tonight

**Leader by magnitude: AEHR +17.6%.** Intel is the catalyst for the whole complex.

| Ticker | Nov-2 close | Nov-2 % | Pre-market | % | Mkt cap | Note |
|---|---|---|---|---|---|---|
| **INTC** | 59.97 | **-8.8%** | **62.20** | **+3.7%** | 317,008M | Second day of a rout, now bouncing. Q4 guide $15-16B vs ~$17B expected; adj EPS $0.25 vs $0.43; gross margin to 38% from 43%; client revenue to fall >20% sequentially; **data centre +78% to $7.3B**. |
| **AMD** | 466.84 | **-7.5%** | **482.92** | **+3.4%** | 762,105M | **Reports after the close.** Consensus rev **$13.08-13.09B** (+42% y/y), adj EPS **$1.95**, GM guide ~56%; Q4 consensus rev $16.29B, EPS $2.68. |
| **NVDA** | 202.06 | -1.3% | **205.94** | **+1.9%** | 4,869,646M | 119.3M shares traded Monday. |
| **LSCC** | 95.44 | +2.7% | **105.95** | **+11.0%** | 13,555M | — |
| **AEHR** | 51.47 | -6.2% | **60.55** | **+17.6%** | 1,681M | AI-driven burn-in/test demand; FY27 outlook raised to $150M (3x FY26). |
| **HLIT** | 10.19 | -0.4% | **11.96** | **+17.4%** | 1,111M | — |
| **NOK** | 8.30 | -3.0% | **8.49** | **+2.3%** | 48,627M | — |

**Read:** the market has drawn a line between *PC* and *AI*. Intel's own data centre grew 78% and its stock still fell 8.8% because client revenue has a -20% sequential guide and management says the PC slump runs through at least 1H 2027. Today's bounce is AMD putting a floor under the group ahead of tonight's print — AMD's Client segment (a quarter of revenue) is the line the Oct 30 selloff priced in, and its Data Center (58% of Q2 revenue) is the line that can re-rate it. **A beat that is all Client is a different story from a beat that is all Data Center.**

**Sources:** [Intel spooked chip investors — AMD's turn](https://uk.finance.yahoo.com/news/intel-spooked-chip-investors-now-120527422.html) · [AMD Q3 preview](https://www.tradingkey.com/analysis/stocks/us-stocks/262263680-amd-q3-earnings-preview-ai-chip-growth-reverse-tradingkey) · [AMD vs Intel read-through](https://finance.yahoo.com/markets/stocks/articles/amd-stock-fell-11-day-063927845.html) · [Why chip stocks are up today](https://coinpedia.org/crypto-live-news/why-are-chip-stocks-up-today-amd-earnings-hopes-and-bargain-buying-after-selloff/amp/)

### Cluster C — AI capex financing: Oracle's $20B is the template everyone else will follow

**Leader: ORCL (flat pre-market at $119.23 after -8.8% Monday).**

- **The deal:** 86,206,897 shares at **$116.00** (11.2% below the Oct 30 close of $130.67, 2.7% below Monday's) plus **$10B of senior notes** in five tranches — $2.0B 7.000% due 2029, $1.75B 7.450% due 2031, $2.25B 7.850% due 2033, $2.5B 8.000% due 2037, $1.5B 8.650% due 2046 — about **$777M a year** of interest. Both sales close **Nov 4**.
- **Why it matters beyond Oracle:** this uses the **entire** $20B FY27-FY30 funding cap Oracle set on Oct 28, split half equity / half debt, and Oracle said in February and June it did not expect to issue bonds or debt in 2026. Oracle has already raised $50B this year ($25B bonds, $5B preferred, $20B stock).
- **The balance sheet behind it:** capex went from **$21.2B in FY2025 to $55.7B in FY2026**, with $28.5B spent in the August quarter alone; borrowings were **$125.34B** at Aug 31 plus **$288B** of lease commitments, substantially all data centres. Free cash flow is guided positive only in H2 FY2028, ≥$30B in FY2029, on FY2030 revenue of ≥$225B.
- **The price:** 86.2M shares is ~2.9% dilution and takes the share count back **above its June 2020 level** at a company that spent a decade shrinking it. At **$119.23** pre-market the market is only **2.8% above the $116 offering price** — the dilution is priced, but the cushion is thin.

**Read:** the AI buildout is now visibly being funded with shareholder dilution and 7-8.65% debt, and Monday's -8.8% was the market repricing **financing cost**, not AI demand. The corroborating read-through is **AAPL -3.9%** on memory costs and **NVDA +1.9%** — capital is still available for the compute, but the balance-sheet risk has moved to the platforms building the data centres. This is the cluster to watch for contagion: Oracle's capex is funding capacity *for AMD, Meta, NVIDIA, OpenAI, TikTok, xAI and others*.

**Source:** [Oracle prices $20B](https://seekingalpha.com/news/4663122-oracle-prices-20b-stock-and-bond-offering-amid-ai-expansion-sets-share-sale-at-116) · [StockTitan: share sale priced at $116](https://www.stocktitan.net/articles/oracle-stock-sale-2026-share-count-back-above-2020) · [Yahoo: $10B stock sale at $116](https://finance.yahoo.com/markets/stocks/articles/oracle-prices-10-billion-stock-121801477.html)

### Cluster D — Marvell/Lumentum: a $115B all-stock deal with a wide, persistent spread

**Leader: LITE (the wider loser at -18.6% Monday).**

| Ticker | Nov-2 close | Nov-2 % | Pre-market | % | Mkt cap |
|---|---|---|---|---|---|
| **MRVL** | 171.41 | **-12.7%** | **176.28** | **+2.8%** | 150,309M |
| **LITE** | 684.40 | **-18.6%** | **700.50** | **+2.4%** | 61,995M |

- **The deal (8-K, Nov 2):** Marvell acquires Lumentum in an all-stock transaction. Lumentum holders receive a **fixed 4.500** MRVL shares per LITE share. Implied enterprise value **$115B**, implied value **~$1,132 per LITE share**, a **23.9% premium** to the Oct 28 unaffected close. Pro-forma ownership **67% MRVL / 33% LITE**. Unanimous board approval. Expected to close **1H CY2028**, subject to both shareholder votes and regulatory approval. Combined EV **over ~$275B**; companies point to a **$550B 2030 TAM**, **>$1B annual run-rate synergies** (mostly COGS), non-GAAP gross margin 57% and operating margin 39% pro-forma, accretive to MRVL non-GAAP EPS in year one. Matt Murphy stays CEO/Chairman; three Lumentum directors, including CEO Michael Hurlston, join the board.
- **The spread today:** at **MRVL $176.28**, the implied LITE value is **4.500 x $176.28 = $793.26**. LITE prints **$700.50** — a **-11.7%** discount to deal value, or **$92.76 per share** of spread.
- **Read:** both legs fell hard on the *day of* the announcement (MRVL -12.7%, LITE -18.6%), which is unusual for a fixed-ratio deal where one leg should rise and the other fall. The market sold the acquirer for raising $115B of equity-linked consideration and sold the target because a fixed ratio hands LITE holders MRvell's price risk. The spread that persists is **not** arbitrage — deal capital is locked until 1H CY28 — so an 11.7% discount is the market pricing **deal or regulatory risk**, or doubting MRVL's own price. Monday's close of $171.41 was 12.7% below the unaffected $196.40: the acquirer's price *is* the spread.

**Sources:** [MRVL/LITE 8-K EX-99.1](https://investor.marvell.com/sec-filings/all-sec-filings/content/0001193125-26-442714/d81187dex991.htm) · [8-K EX-99.2 investor deck](https://investor.marvell.com/sec-filings/all-sec-filings/content/0001193125-26-442714/d81187dex992.htm) · [RTTNews on the reaction](https://www.rttnews.com/3707270/marvell-technology-stock-falls-6-after-announcing-lumentum-acquisition.aspx)

### Cluster E — Psychedelics and FDA: the winners of October are giving the gains back

**Leader today: CMPS +6.9%.** Monday's tape was the opposite: INO +213.7%, PGEN -25.9%.

- **CMPS (the live story).** Compass Pathways reported **Q3 2026 this morning** (call 8:00 ET). The final **NDA submission will be filed in the next two weeks**, with rolling review already underway. **National Priority Voucher** review could compress the timeline to **1-2 months**, and a White House executive order directs the DEA to support rapid rescheduling after successful Phase 3 data. Launch remains targeted for **H1 2027**; the commercial build is in place; COMP360 should drop into an existing network of **8,500+** treatment centres. R&D was $23.5M vs $27.3M a year ago. Pre-market **$8.99, +6.9%** after **-27.3%** Monday, when a report that nonprofit Usona had filed an FDA application for psilocybin in major depression triggered fears of a faster rival path (note: Usona's target is MDD, COMP360 is treatment-resistant depression). Jefferies had put approval odds at 75-85%.
- **INO (the fade).** INOVIO's **VOCERYQ** — the first FDA-approved plasmid DNA immunotherapy, for recurrent respiratory papillomatosis — was approved on **accelerated approval** after Friday's close, with an investor call Nov 2. Monday: **+213.7%** to $1.89. Today: **-7.9%** at $1.74. Pricing is **~$115,000 per dose / $460,000 for the four-dose series**, shipments in ~60 days, full commercial deployment in Q1 2027 — and continued approval is contingent on a confirmatory study.
- **The rest of the RRP complex:** **PGEN -25.9%** Monday (direct competitor) is **+1.8%** today; **DRUG -52.3%** Monday is **-9.6%** today; **KPTI -83.1%** Monday (Chapter 11) is **-6.2%** today at $0.1051, still down 6.2% on 1.6M pre-market shares.

**Read:** the FDA/psychedelic complex is rotating out of the approval winner and into the commercial-catalyst names. CMPS is now the tradeable event because it has a *dated* catalyst — an NDA filing inside two weeks against a 1-2 month review clock — while INO's approval is already in the price and its risk is a confirmatory study, not a launch.

**Sources:** [Compass Pathways Q3 2026 results](https://www.businesswire.com/news/home/20261103539380/en/) · [Compass IR: Q3 date](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-to-Announce-Third-Quarter-2026-Financial-Results-on-November-3-2026/default.aspx) · [BioSpace: FDA psychedelic hearing](https://www.biospace.com/fda/psychedelic-therapies-ride-wave-of-public-favor-into-fda-hearing) · [INOVIO: FDA accelerated approval of VOCERYQ](https://ir.inovio.com/news/news-details/2026/INOVIO-Announces-FDA-Accelerated-Approval-of-VOCERYQ-an-Immunotherapy-to-Reduce-the-Frequency-of-Surgery-in-Adults-with-Recurrent-Respiratory-Papillomatosis-RRP/default.aspx) · [MedCity News on VOCERYQ](https://medcitynews.com/2026/11/inovio-voceryq-fda-approval-dna-immunotherapy-human-papillomavirus-papilloma-hpv-rrp-ino/)

### Cluster F — Single-name idiosyncratic / event-driven

- **EVGO +46.8%** Monday (closed $1.85) on LS Power agreeing to take it private at **$2.00/share cash**; pre-market **$1.80, -2.6%** — still **9.9% below the deal price**. Source: prior run's artifact `daily-briefs/2026-11-02-pre-market.md` (cluster A, Nov 2).
- **IDXX +21.9%** Monday (closed $671.64) **after raising its outlook**; pre-market $668, -0.5% on trivial volume. Source: Saxo Market Quick Take, Nov 3.
- **PERI +31.1%** Monday (closed $11.41) on a 6-K; pre-market flat. Source: prior run's artifact.
- **Consumer/transport earnings reactions, catalysts not individually sourced in this run:** **NWL +15.1%**, **ULCC +15.2%**, **SFM +11.1%**, **AAL +3.8%**, **RIVN +8.5%** — all Monday, all now flat in the pre-market.

---

## 3. Pre-market gaps — top 25 market-wide (Tue 2026-11-03, liquidity-screened)

Screen: pre-market volume ≥100,000 shares, **or** market cap ≥$200M with ≥10,000 pre-market shares. `%ADV` = pre-market volume ÷ 30-day average volume.

| Ticker | Name | Pre-market | % | Pm vol | %ADV | Mkt cap | Sector | Nov-2 close | Nov-2 % |
|---|---|---|---|---|---|---|---|---|---|
| **RDAC** | Rising Dragon Acquisition Corp. | 11.2 | +119.6% | 4,079,874 | 40157% | 18M | Finance | 5.1 | +2.8% |
| **MERC** | Mercer International Inc. | 0.2348 | +86.3% | 116,867,017 | 5119% | 8M | Process Industries | 0.126 | +5.0% |
| **SGRX** | SANGRIX INC. | 1.0375 | +40.6% | 25,145,325 | 265% | 3M | Consumer Non-Durables | 0.738 | +0.6% |
| **HUBC** | Hub Cyber Security Ltd. | 0.114 | +39.0% | 143,789,132 | 1481% | 0M | Commercial Services | 0.082 | -27.7% |
| **BLZE** | Backblaze, Inc. | 10.1485 | +37.1% | 301,384 | 14% | 458M | Electronic Technology | 7.4 | -2.5% |
| **INLF** | INLIF LIMITED | 0.385 | +32.8% | 42,574,746 | 146% | 0M | Producer Manufacturing | 0.2899 | +56.7% |
| **EHGO** | Eshallgo Inc. | 2.3402 | +22.5% | 1,885,044 | 1309% | 2M | Distribution Services | 1.91 | -4.5% |
| **BRAI** | Braiin Limited | 2.99 | +19.6% | 933,923 | 22% | 515M | Technology Services | 2.5 | +2.0% |
| **CRE** | Cre8 Enterprise Limited | 2.96 | +18.6% | 107,795 | 90% | 5M | Commercial Services | 2.495 | +1.4% |
| **AEHR** | Aehr Test Systems | 60.55 | +17.6% | 174,660 | 7% | 1,681M | Electronic Technology | 51.47 | -6.2% |
| **HLIT** | Harmonic Inc. | 11.96 | +17.4% | 29,408 | 2% | 1,111M | Electronic Technology | 10.19 | -0.4% |
| **IBTA** | Ibotta, Inc. | 58.01 | +15.9% | 12,354 | 5% | 1,160M | Technology Services | 50.07 | +3.0% |
| **CMCO** | Columbus McKinnon Corporation | 18.24 | +15.7% | 13,498 | 3% | 455M | Producer Manufacturing | 15.76 | +5.3% |
| **LSCC** | Lattice Semiconductor Corporati | 105.95 | +11.0% | 164,349 | 8% | 13,555M | Electronic Technology | 95.44 | +2.7% |
| **GRAB** | Grab Holdings Limited | 3.16 | +10.5% | 7,175,449 | 10% | 11,665M | Transportation | 2.86 | +5.5% |
| **GOVX** | GeoVax Labs, Inc. | 0.1799 | +10.4% | 212,419 | 31% | 2M | Health Technology | 0.163 | -3.3% |
| **RVTY** | Revvity, Inc. | 167 | +10.2% | 10,467 | 1% | 16,916M | Health Technology | 151.6 | -3.4% |
| **FISV** | Fiserv, Inc. | 57.08 | +9.9% | 334,387 | 5% | 27,615M | Commercial Services | 51.93 | +3.8% |
| **AHCO** | AdaptHealth Corp. | 6.49 | +9.8% | 18,363 | 1% | 806M | Health Services | 5.91 | +1.7% |
| **GPK** | Graphic Packaging Holding Compa | 10.2 | +9.3% | 16,573 | 0% | 2,762M | Process Industries | 9.33 | +4.2% |
| **MDGL** | Madrigal Pharmaceuticals, Inc. | 470 | +9.0% | 13,065 | 4% | 9,961M | Health Technology | 431.155 | +0.2% |
| **LIFE** | Ethos Technologies Inc. | 46.41 | +8.9% | 79,835 | 5% | 2,770M | Technology Services | 42.62 | -1.8% |
| **WYHG** | Wing Yip Food Holdings Group Li | 2.97 | +8.8% | 2,269,680 | 6450% | 29M | Consumer Non-Durables | 2.73 | -0.4% |
| **XMAX** | XMAX, Inc. | 4.3519 | +8.5% | 39,340 | 4% | 260M | Consumer Durables | 4.01 | -37.5% |
| **PARA** | Parabolic Technologies, Inc. | 1.82 | +7.7% | 1,683,296 | 399% | 1M | Technology Services | 1.69 | -46.7% |

*Screen pass: 66 gainers of 262 names ≥+3% pre-market. The list is topped by sub-$0.40 microcaps (RDAC +119.6% on a $18M cap, MERC +86.3% on $8M) whose reported pre-market volumes are not trustworthy — see Source health. The cleanest large-cap movers are AEHR, HLIT, IBTA, CMCO, LSCC, GRAB, RVTY, FISV and GPK.*

### Context — Monday's (Nov 2) session, the tape that set today's gaps

**Nov 2 gainers (top 10):**

| Ticker | Name | Close | % | Volume | Mkt cap | Sector | Now (pre) |
|---|---|---|---|---|---|---|---|
| INO | Inovio Pharmaceuticals, Inc. | 1.89 | +213.7% | 222,247,332 | 195M | Health Technology | -7.9% |
| VCIG | VCI Global Limited | 8.16 | +168.4% | 6,413,280 | 4M | Commercial Services | -38.5% |
| CLRO | ClearOne, Inc. | 5.65 | +65.7% | 39,090,653 | 15M | Consumer Durables | -12.9% |
| INLF | INLIF LIMITED | 0.2899 | +56.7% | 471,191,583 | 0M | Producer Manufacturing | +32.8% |
| EVGO | EVgo Inc. | 1.85 | +46.8% | 72,258,156 | 582M | Retail Trade | -2.6% |
| SEGG | Sports Entertainment Gaming Gl | 1.93 | +45.1% | 35,316,519 | 7M | Consumer Services | -3.6% |
| HXHX | Haoxin Holdings Limited | 0.236 | +38.9% | 56,683,735 | 3M | Transportation | -28.0% |
| IFBD | Infobird Co., Ltd | 1.03 | +37.8% | 1,107,206 | 8M | Technology Services | -1.0% |
| NMRA | Neumora Therapeutics, Inc. | 0.4957 | +35.0% | 5,824,536 | 93M | Health Technology | -2.5% |
| GNTA | Genenta Science S.p.A. | 0.8166 | +32.1% | 1,575,055 | 39M | Electronic Technology | -0.2% |

**Nov 2 losers (top 10):**

| Ticker | Name | Close | % | Volume | Mkt cap | Sector | Now (pre) |
|---|---|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | 0.112 | -83.1% | 47,436,550 | 3M | Health Technology | -6.2% |
| WHLR | Wheeler Real Estate Investment | 0.611 | -60.3% | 2,578,173 | 1M | Finance | -5.6% |
| DRUG | Bright Minds Biosciences Inc. | 26.2 | -52.3% | 1,827,133 | 258M | Health Technology | -9.6% |
| AIOK | AI OKTO CORP. | 12.63 | -47.7% | 2,222,334 | 0M | Transportation | -11.8% |
| PARA | Parabolic Technologies, Inc. | 1.69 | -46.7% | 8,584,554 | 1M | Technology Services | +7.7% |
| JAGX | Jaguar Health, Inc. | 0.8841 | -45.4% | 2,203,989 | 2M | Health Technology | -30.4% |
| JDZG | JIADE LIMITED | 0.5264 | -43.8% | 4,080,800 | 3M | Commercial Services | -24.2% |
| MTEN | Mingteng International Corpora | 0.5003 | -41.4% | 769,801 | 4M | Producer Manufacturing | -6.1% |
| RCT | RedCloud Holdings plc | 0.0351 | -39.2% | 26,345,463 | 3M | Technology Services | -12.8% |
| XMAX | XMAX, Inc. | 4.01 | -37.5% | 4,476,690 | 260M | Consumer Durables | +8.5% |

---

## 4. Top losers — top 10 market-wide (Tue 2026-11-03 pre-market, liquidity-screened)

| Ticker | Name | Pre-market | % | Pm vol | %ADV | Mkt cap | Sector | Nov-2 close | Nov-2 % |
|---|---|---|---|---|---|---|---|---|---|
| **VCIG** | VCI Global Limited | 5.02 | -38.5% | 141,013 | 21% | 4M | Commercial Services | 8.16 | +168.4% |
| **JAGX** | Jaguar Health, Inc. | 0.615 | -30.4% | 669,569 | 14% | 2M | Health Technology | 0.8841 | -45.4% |
| **HXHX** | Haoxin Holdings Limited | 0.1699 | -28.0% | 984,854 | 24% | 3M | Transportation | 0.236 | +38.9% |
| **JDZG** | JIADE LIMITED | 0.3991 | -24.2% | 503,874 | 25% | 3M | Commercial Services | 0.5264 | -43.8% |
| **BDMD** | Baird Medical Investment Holdin | 0.1065 | -22.8% | 3,806,132 | 62% | 4M | Health Technology | 0.138 | -14.0% |
| **SHFS** | SHF Holdings, Inc. | 0.0365 | -21.0% | 14,329,428 | 16% | 1M | Finance | 0.0462 | -25.6% |
| **ADEA** | Adeia Inc. | 16.35 | -20.9% | 53,671 | 5% | 2,279M | Technology Services | 20.67 | -3.6% |
| **GMEX** | GMEX ROBOTICS CORPORATION | 0.695 | -20.7% | 135,973 | 15% | 1M | Retail Trade | 0.8769 | +3.2% |
| **EBS** | Emergent BioSolutions Inc. | 5.2 | -19.3% | 10,146 | 1% | 330M | Health Technology | 6.44 | -5.4% |
| **SHOP** | Shopify Inc. | 133.39 | -14.6% | 821,746 | 9% | 200,965M | Commercial Services | 156.22 | -0.8% |

*Screen pass: 44 decliners of 203 names ≤-3% pre-market. **Seven of the ten are software or consumer-tech**, and four of those (ADEA, SHOP, DT, plus EBS) are Q3 reporters — this is a single earnings cluster, not a broad de-risking. The five largest moves in the list (VCIG -38.5%, JAGX -30.4%, HXHX -28.0%, JDZG -24.2%, BDMD -22.8%) are all sub-$5M caps and 1-4M-share names.*

---

## 5. StockTwits lead read — trending (15)

Lead indicator, not a sidebar. Every row was price-checked against the pre-market tape.

| # | Ticker | Score | Nov-2 close (chg) | Pre-market | %ADV | Thesis (StockTwits, published 08:33 ET snapshot) |
|---|---|---|---|---|---|---|
| **PLTR** | 14.52 | 178.34 (-3.1%) | 167.4335 (-6.1%) | 9% of 30d ADV | Palantirs strong Q3 results and raised outlook were followed by a sharp selloff, with traders debating whether its rich valuation and slower contract-value growth undermine the durability of the growth story. Bulls point to accelerating commercial AI demand, while bears argue that strong results may |
| **SHOP** | 12.21 | 156.22 (-0.8%) | 133.39 (-14.6%) | 9% of 30d ADV | Shopifys quarterly report sparked a sharp selloff despite solid headline results, as traders focused on a slight GMV and gross-profit shortfall, moderating growth, and a high valuation. Some see the reaction as an overreaction given continued business growth and strong cash generation, while others  |
| **CMPS** | 11.90 | 8.41 (-27.3%) | 8.99 (+6.9%) | 6% of 30d ADV | Reports that nonprofit Usona has submitted an FDA application for psilocybin in major depressive disorder have fueled fears that a rival could get ahead of Compass in the psychedelic-drug race, amid CMPSs steep selloff. Traders disagree on the threat: some see competition and a potential first-mover |
| **UPST** | 11.61 | 21.31 (-7.4%) | 20.2266 (-5.1%) | 28% of 30d ADV | Upstarts Q3 results and outlook are driving attention: traders cite stronger loan growth and renewed profitability, but many are focused on lower guidance and a weak outlook as shares sell off. The debate centers on whether operating progress can outweigh rate, credit-quality, and funding concerns. |
| **ORCL** | 11.17 | 119.22 (-8.8%) | 119.2315 (+0.0%) | 10% of 30d ADV | Oracles stock-and-bond fundraising for its AI infrastructure buildout is driving the selloff, with traders debating dilution, borrowing costs and whether future AI revenue can justify the spending. Some see the raise as a necessary, previously outlined step that clears the way for growth, while othe |
| **LKNCY** | 11.17 | 31.2 (+0.9%) | 33.28 (+6.7%) | 1% of 30d ADV | Luckins Q3 results are driving discussion, with traders welcoming stronger profitability and margins alongside continued revenue growth and a new share-repurchase authorization. The reaction is mixed: bulls see improving earnings quality, while skeptics point to declining same-store sales and questi |
| **BLZE** | 10.04 | 7.4 (-2.5%) | 10.1485 (+37.1%) | 14% of 30d ADV | Backblazes Q3 results beat expectations and the company raised its outlook, with accelerating B2 cloud-storage growth drawing attention as an AI-infrastructure tailwind. Traders are split between bullish reactions to the growth and guidance and concerns about profitability, retention, and the sharp  |
| **PFE** | 9.36 | 30.67 (+0.5%) | 30.6594 (-0.0%) | 3% of 30d ADV | Pfizers quarterly results beat expectations and the company raised its full-year outlook, with traders highlighting growth in newer and acquired products as evidence of progress beyond COVID-related sales. Reactions are mixed: some see a stronger growth story, while others argue the outlook is large |
| **FISV** | 8.96 | 51.93 (+3.8%) | 57.08 (+9.9%) | 5% of 30d ADV | Fiservs quarterly results, which traders described as beating expectations, alongside reaffirmed full-year guidance and stepped-up cost-cutting and buyback plans, have fueled a rebound. The community is split between viewing the new CEOs moves as signs of a turnaround and doubting the recovery while |
| **AMD** | 8.36 | 466.84 (-7.5%) | 482.92 (+3.4%) | 2% of 30d ADV | AMDs upcoming earnings report and forward guidance are the focus after a sharp selloff alongside chip stocks following Intels weak outlook. Traders are divided over whether strong results and guidance can reassure investors and support the broader semiconductor sector, or whether market caution will |
| **DOCN** | 7.01 | 89.79 (+0.2%) | 84 (-6.4%) | 28% of 30d ADV | (no StockTwits thesis published) |
| **ET** | 6.94 | 20.34 (-2.7%) | 20.5895 (+1.2%) | 1% of 30d ADV | (no StockTwits thesis published) |
| **AEHR** | 6.86 | 51.47 (-6.2%) | 60.55 (+17.6%) | 7% of 30d ADV | (no StockTwits thesis published) |
| **IEP** | 6.64 | 5.16 (-0.6%) | 5.6 (+8.5%) | 8% of 30d ADV | (no StockTwits thesis published) |
| **OUST** | 6.55 | — | — | — | (no StockTwits thesis published) |

*Theses are StockTwits' own auto-summaries of retail discussion, carried verbatim and truncated; they are sentiment, not verified fact. Every number in the two middle columns is a fetched price.*

---

## 6. Watchlist

**Not published — the watchlist file is missing in this runtime.** The skill's watchlist (`research/watchlist.yaml`) lives on the local Windows Mavis host; it is not present in the Cloud sandbox and no copy exists in `karizaco/maxhermes-migration` (the repo contains no `.yaml`/`.yml` file) or in `karizaco/minimax-cloud-outputs`. Per the skill: no default watchlist was created, and the gap is surfaced in Source health.

---

## 7. Overnight — futures, indices, FX, crypto

| Instrument | Last | Prior close | % | As of (UTC) |
|---|---|---|---|---|
| S&P 500 futures (Dec) | 7571.5 | 7574.5 | -0.04% | 2026-11-03T13:27:15.000Z |
| Nasdaq 100 futures (Dec) | 28263 | 28127.5 | +0.48% | 2026-11-03T13:27:15.000Z |
| Dow futures (Nov) | 51822 | 52133 | -0.60% | 2026-11-03T13:27:15.000Z |
| Russell 2000 futures (Nov) | 2823 | 2817.8 | +0.18% | 2026-11-03T13:27:12.000Z |
| WTI crude (Dec) | 96.78 | 96.46 | +0.33% | 2026-11-03T13:27:13.000Z |
| Gold (Dec) | 3950.1 | 3969.6 | -0.49% | 2026-11-03T13:27:14.000Z |
| Bitcoin | 77490.86 | 76683.89 | +1.05% | 2026-11-03T13:37:12.000Z |
| VIX (indicative overnight) | 21.49 | 21.15 | +1.61% | 2026-11-03T13:22:01.000Z |
| US Dollar Index | 101.818 | 101.745 | +0.07% | 2026-11-03T13:27:14.000Z |
| US 10Y yield | 4.927 | 4.894 | +0.67% | 2026-11-03T13:22:05.000Z |
| US 5Y yield | 4.72 | 4.693 | +0.58% | 2026-11-03T13:22:05.000Z |

| Index | Last | Prior close | % | As of (UTC) |
|---|---|---|---|---|
| S&P 500 (Nov 2 close) | 7541.4 | 7580.07 | -0.51% | 2026-11-02T21:50:59.000Z |
| Nikkei 225 | 63081.86 | 63290.1 | -0.33% | 2026-11-02T06:45:03.000Z |
| Shanghai Composite | 3608.098 | 3638.031 | -0.82% | 2026-11-03T07:00:25.000Z |
| Hang Seng | 23525.97 | 23393.32 | +0.57% | 2026-11-03T08:08:30.000Z |
| KOSPI | 5648.79 | 5859.08 | -3.59% | 2026-11-03T11:05:40.000Z |
| TAIEX | 43307.54 | 44920.14 | -3.59% | 2026-11-03T05:33:15.000Z |
| FTSE 100 | 10683.11 | 10761.33 | -0.73% | 2026-11-03T13:22:15.000Z |
| DAX | 25842.55 | 25981.09 | -0.53% | 2026-11-03T13:22:15.000Z |
| EURO STOXX 50 | 6149.6 | 6176.06 | -0.43% | 2026-11-03T13:22:15.000Z |

| US ETF (Nov 2 close) | Close | Prev | % | As of (UTC) |
|---|---|---|---|
| SPY | 752.1 | 755.72 | -0.48% | 2026-11-02T21:00:00.000Z |
| QQQ | 681.09 | 690.49 | -1.36% | 2026-11-02T21:00:00.000Z |
| DIA | 519.34 | 517.13 | +0.43% | 2026-11-02T21:00:00.000Z |
| IWM | 279.14 | 279.33 | -0.07% | 2026-11-02T21:00:00.000Z |
| XLK | 174.22 | 179.51 | -2.95% | 2026-11-02T21:00:00.000Z |
| XLF | 57.56 | 56.51 | +1.86% | 2026-11-02T21:00:00.000Z |
| XLI | 169.71 | 167.4 | +1.38% | 2026-11-02T21:00:00.000Z |
| SMH | 508.31 | 522.49 | -2.71% | 2026-11-02T21:00:01.000Z |
| XBI | 152.05 | 155.98 | -2.52% | 2026-11-02T21:00:00.000Z |
| TLT | 81.73 | 81.4968 | +0.29% | 2026-11-02T21:00:00.000Z |
| GLD | 361.65 | 355.78 | +1.65% | 2026-11-02T21:00:00.000Z |
| HYG | 76.89 | 77.0286 | -0.18% | 2026-11-02T21:00:00.000Z |
| ARKK | 78.96 | 80.75 | -2.22% | 2026-11-02T21:00:00.000Z |

**Read:** Monday was a **rotation, not a sell-off** — the Dow rose 0.43% while the Nasdaq-100 fell 1.36% and the S&P 500 fell 0.51%, and the SOX complex took the worst of it (XLK -2.95%, SMH -2.71%, against XLF +1.86% and XLI +1.38%). Overnight, **futures are mixed and the leadership has flipped (ES -0.04%, NQ +0.48%, YM -0.60%)** — the Dow future is the weakest and the Nasdaq future the strongest, the *opposite* of Monday. **10Y at 4.927%** (+3.3bp vs Monday's 4.894%), DXY 101.818, **WTI $96.78 +0.33%**, gold $3,950 -0.49%, **Bitcoin $77,491 +1.05%**, **VIX 21.49** indicative. Asia was weak where tech is heaviest: **KOSPI -3.59%** to 5,648.79 and **TAIEX -3.59%**, with Shanghai -0.82% and Nikkei -0.33%; Hang Seng +0.57%. Europe is lower mid-session (FTSE -0.73%, DAX -0.53%, EURO STOXX 50 -0.43%) — softer than the early European open, which had been carried by the oil move.

---

## 8. Macro calendar

- **US midterm elections today (Nov 3).** All 435 House seats and 35 Senate seats. First polls close ~18:00 ET (Indiana/Kentucky), major states 19:00-20:00 ET (FL/GA/VA 19:00; OH/NC 19:30; ME/MI/PA/TX 20:00) — **everything lands after the cash close**.
- **Priced:** Democratic sweep ~66%, Democratic House + Republican Senate ~27%, Republican sweep ~9% (prediction markets, as of Oct 29-30); UBS puts 50% / 40% / 10%. A clean Democratic result is largely in the price, so the **surprise** scenario is the risk.
- **Vol pricing:** options price ~0.86% for today and 1.85% into Nov 6; SPX options imply ~0.8% for Wednesday vs a 0.6% one-month average. VIX 21.15 closed Monday, nine-day vol 22.46 (above spot), skew elevated at 152.78.
- **Next on the tape:** Wednesday's refunding, **Friday Nov 6 payrolls** (hot = yields higher), CPI Nov 10, and a December Fed hike is now the base case after September's hike. **10Y 4.927%, WTI $96.78, Brent above $110** on the Iran war. A Democratic Congress raises the odds of **oversight of the AI/data-centre buildout** — the market-sensitive AI trade.
- **Overnight macro:** the **RBA hiked** and shifted dovish on guidance.

---

## 9. Earnings today

- **243 companies report today — 103 before the open, 140 after the close** (EarningsWhispers). Already in the tape: **SHOP, PFE, ZBRA, DT, DOCN, CMPS, RVTY, AEHR, ADEA, GRAB** (before the open or Mon after the close).
- **After the close today: AMD** — consensus revenue **$13.08-13.09B** (+42% y/y), adj EPS **$1.95**, non-GAAP GM guide ~56%, call 17:00 ET. This is the day's highest-conviction event and it sets the tone for the whole semi complex into Nov 4.
- **Also after the close:** AMGN, ANET, BKNG, MPC, APO, BRK-B, DELL, ADI, ADSK, ZS, HPQ, BBY, DKS.
- **Next two days:** **ARM Nov 4**, **PGEN Nov 4** (R1) — the direct RRP competitor to INOVIO — and INO Nov 10.
- **Biggest names already reported:** AAPL (Mon PM), PLTR (Mon PM), INO/ADEA/AEHR (Mon PM), SHOP/PFE/ZBRA/DT/DOCN/CMPS/RVTY (Tue AM).

---

## 10. Source health

| Source | Query / URL | Status | Notes |
|---|---|---|---|
| MCP availability probe | `probe_mcp.py` | **ok** | `catalog_ok total=135 finance_tools=0` — no finance MCP registered on the platform. **Not an error.** |
| MCP-over-HTTP bridge (`stocktwits`) | `trending_symbols`, limit=15 | **ok** | HTTP 200, 15 rows with thesis summaries. Bridge packs: tradier, fmp, market-recap. |
| MCP-over-HTTP bridge (`market-recap`) | `get_quotes` x5, `market_snapshot`, `top_movers` | **ok** | Quote source of record for regular-session closes. |
| TradingView public scanner | `POST scanner.tradingview.com/america/scan` x6 | **ok** | Pre-market prices, %ADV, market cap. **First call returned HTTP 400** — the filter operator `in` is unsupported; `in_range` works. Not a source failure. |
| TradingView `change` column units | identity check `close − close/(1+change/100) == change_abs` | **ok** | `change` is in **percent** units, not a fraction. |
| `web_search` | 11 queries | **ok** | 5 cluster anchors + 5 single-name verifications + 1 macro/election. |
| `web_fetch` | earningswhispers.com/calendar/20261103 | **failed** | "file load failed" — roster taken from the search-indexed page instead; before/after-open counts (103/140) are from that snippet. |
| **Watchlist file** | `research/watchlist.yaml` | **missing** | Not in the sandbox, not in either repo. No default created (§6). |
| OTC coverage | `LKNCY` | **partial** | The `america` scan is NASDAQ/NYSE/AMEX only. LKNCY pulled separately: **$33.28, +6.7%** pre-market (closed $31.20 Monday, +0.9%). |

**Data caveats that change how this should be read**

1. **Pre-market volume on sub-$0.50 names is not trustworthy.** TV reports MERC at 116.9M pre-market shares and HUBC at 143.8M on a $0.08-$0.23 stock — implausible counts that inflate %ADV into the thousands of percent. Treat the sub-$1 rows in §3 and §4 as **noise, not liquidity**.
2. **`premarket_time` is a constant** (the 04:00 ET session open), not the last print time, so per-name print staleness cannot be dated from the scanner. The pre-market snapshot is a single point in time at ~08:33 ET and will have moved by the open.
3. **Every regular-session close quoted here was verified twice** — TradingView and the Yahoo-sourced `market-recap` agreed to the cent on all 24 names cross-checked (MRVL, LITE, AAPL, INTC, ORCL, PLTR, SHOP, FISV, AMD, NVDA, ZBRA, DT, ADEA, AEHR, LSCC, CMPS, PGEN, BLZE, DOCN, UPST, GRAB, JD, IVZ, LKNCY).
4. **Catalysts are asserted only where sourced.** For a handful of smaller names (§2 Cluster F, and the mid-table of §3) no catalyst was independently sourced in this run, and none is claimed.
5. **`earnings_release_next_date` is forward-looking and can be stale** for a name that reported today (it has not always rolled). It was used only for scheduling context, never to assert that a company reported.
6. **No `mcp__*` finance tool is registered on this runtime.** Per the runtime contract that is an expected state, not an error, and it is not counted in the error count.

---

## 11. Open research queue

1. **LITE $700.50 vs 4.500 x MRVL $176.28 = $793.26 — an 11.7% spread.** Deal capital is locked to 1H CY28, so this is not arbitrageable; the question for the next session is whether the discount narrows on the open or whether MRVL itself keeps falling and drags the implied value down. A widening spread on a rising MRVL would signal deal risk rather than sentiment.
2. **ORCL $119.23 vs the $116.00 offering price — a 2.8% cushion.** Both halves of the financing close Nov 4. If ORCL trades below $116 the offering did not clear at the posted price and Oracle must either re-price or absorb the difference.
3. **AMD's Client line is the trade.** Consensus revenue $13.08-13.09B with Q2 Client at $3.1B and Q2 Data Center at $6.7B (58% of revenue). A Client number near $3.1B confirms the Oct 30 PC read-through was right and the AI engine is not enough; a Data Center beat at ~56% GM re-rates the whole complex into Nov 4.
4. **CMPS's NDA filing is the dated catalyst.** Final submission due within two weeks against a National Priority Voucher review that could compress to 1-2 months, with launch targeted for H1 2027. A slip past the two-week window removes the only time-bound event the name has.
5. **SPX closed 7,541.40 on Nov 2 (-0.51%), already below the ~7,604 100-day average Reuters cites** (with ~7,507 as the next reference level). Add the election count on top of a tape where the Nasdaq-100 is in correction territory, and the 09:30 open is the first real test of whether Monday was rotation or the start of a de-risking week.

---

*Generated by Cloud Mavis cron #26 (`agentic-pre-market-brief`) on 2026-11-03. Read-only research brief — no trades, no positions. Every percentage traces to a fetched value or a cited source; the full pre-market screen is in `daily-briefs/2026-11-03-pre-market.csv`.*